The purpose of this study is to assess the safety of Symbicort compared to Pulmicort in asthmatic children aged 6 to 11 years
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
175
Long term safety profile of Symbicort compared to Pulmicort as determined by safety assessments detailed in the protocol
Time frame: 4 assessments within 26 week treatment period
Compare health economic outcomes and quality of life between patients treated with Symbicort and Pulmicort
Time frame: 4 assessments within 26 week treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.